Buy Protonix through the unique service that maximize your savings

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c81885) has announced the addition of Wyeth: PharmaVitae Profile to their offering.
This analysis examines the historical and forecast performance for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
* Benchmark Wyeths performance against key rivals in the ethical pharmaceutical sector
* Analyze how Wyeth will perform in light of patent expiry for the key Effexor and Protonix franchises prior to 2012
* Assess the forecast transition in Wyeth’s therapeutic focus, as illustrated by the emergence of its infectious diseases portfolio
Content Outline:

Chapter 1 Executive Summary
Chapter 2 Corporate History
Chapter 3 Historical Performance
Chapter 4 Forecast Performance
Chapter 5 Key Products And Competitors
Chapter 6 Appendix

List of Tables
List of Figures

Companies Mentioned:

- Abbott Laboratories
- Amgen Inc.
- Astralis Ltd.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Centro HL Distribuzione S.p.A.
- Eli Lilly and Company
- Genentech, Inc.
- GlaxoSmithKline Plc
- Impax Laboratories, Inc.
- IMS Health
- Insight Communications Company, Inc.
- Johnson & Johnson
- Ligand Pharmaceuticals Incorporated
- Merck & Co., Inc.
- Novartis AG
- Nycomed International Management GmbH
- Pfizer Inc
- Progenics Pharmaceuticals, Inc.
- Solvay Group
- Sun Pharmaceuticals Industries Ltd
- Wyeth

For more information visit http://www.researchandmarkets.com/reports/c81885
Source: Datamonitor
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning